Your session is about to expire
← Back to Search
Hemorrheologic agent
Tocopherol + Pravastatin + Pentoxifylline for Radiation-Induced Lymphedema and Fibrosis
Phase 2
Waitlist Available
Led By Clifton Fuller, MD,PHD
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Patients dispositioned to radiotherapy with prescribed dose to unilateral or bilateral neck(s)
Age ≥18 years. Children are excluded from this study
Must not have
Active liver disease (Child-Pugh class B-C), cirrhosis, nor active alcoholism
History of myopathy/rhabdomyolysis
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion; an average of 1 year.
Awards & highlights
No Placebo-Only Group
Summary
"This trial aims to see if pentoxifylline and vitamin E or pravastatin can help reduce lymphedema and fibrosis caused by radiation."
Who is the study for?
This trial is for individuals who have developed lymphedema or fibrosis as a result of radiation therapy. The specific eligibility criteria are not provided, but typically participants would need to meet certain health standards and may be required to have a history of radiation treatment.
What is being tested?
The study is testing whether pentoxifylline combined with vitamin E (tocopherol) or the drug pravastatin can help reduce symptoms of lymphedema and fibrosis caused by radiation. It's an interventional study where patients are likely randomly assigned to different treatments.
What are the potential side effects?
Possible side effects could include digestive issues, skin reactions, or liver enzyme changes from tocopherol; muscle pain, nausea, headache from pravastatin; and dizziness or gastrointestinal discomfort from pentoxifylline.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am scheduled for radiotherapy targeting my neck.
Select...
I am 18 years old or older.
Select...
I can care for myself but may not be able to do active work.
Select...
My blood counts and liver/kidney functions are within normal ranges.
Select...
My cancer is in the oropharynx and hasn't spread to distant parts of my body.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I do not have severe liver disease, cirrhosis, or active alcoholism.
Select...
I have a history of muscle disease or severe muscle breakdown.
Select...
I have had a heart attack or severe heart disease.
Select...
I am either pregnant, post-menopausal, or male.
Select...
I have a history of diabetes.
Select...
I am allergic to certain cholesterol medications and/or xanthine derivatives.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion; an average of 1 year.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion; an average of 1 year.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Safety and adverse events (AEs)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Group I: Group 2Experimental Treatment2 Interventions
Beginning at 6 months after radiation therapy, participants will take pentoxifylline and vitamin E by mouth 3 times a day for about 12 months.
Group II: Group 1Experimental Treatment1 Intervention
Beginning at 6 months after radiation therapy, participants will take 40 mg pravastatin by mouth 1 time a day for about 12 months.
Group III: Group 3Active Control1 Intervention
Participants will not be given any of the study drugs, as this is the control group.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pravastatin
2010
Completed Phase 4
~11530
Pentoxifylline
2021
Completed Phase 4
~1080
Tocopherol
1993
Completed Phase 4
~220
Find a Location
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
3,070 Previous Clinical Trials
1,802,513 Total Patients Enrolled
Clifton Fuller, MD,PHDPrincipal InvestigatorM.D. Anderson Cancer Center